Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects

被引：0
|
作者：
Landovitz, R.
Faetkenhauer, G.
Hoffmann, C.
Horst, H.
Strizki, J.
Whitcomb, J.
Gheyas, F.
Knepp, D.
Greaves, W.
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Univ Cologne, Dept Internal Med, D-5000 Cologne 41, Germany
[3] Hosp St George, Dept Internal Med, Hamburg, Germany
[4] Univ Kiel, Dept Internal Med, D-24098 Kiel, Germany
[5] Monogram Biosci Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [21] Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable
    Faetkenheuer, Gerd
    Hoffmann, Christian
    Slim, Jihad
    Rouzier, Regine
    Keung, Anther
    Li, Jing
    Treitel, Michelle
    Sansone-Parsons, Angela
    Kasserra, Claudia
    O'Mara, Edward
    Schuermann, Dirk
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (01) : 78 - 85
  • [22] CCR5 Antagonists in the Treatment of HIV-Infected Persons: Is Their Cancer Risk Increased, Decreased, or Unchanged?
    McNiff, Todd
    Dezube, Bruce J.
    AIDS READER, 2009, 19 (06): : 218 - +
  • [23] Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: results of the EPIC study (CCR100136)
    Yeni, P.
    LaMarca, A.
    Berger, D.
    Cimoch, P.
    Lazzarin, A.
    Salvato, P.
    Smaill, F. M.
    Teofilo, E.
    Madison, S. J.
    Nichols, W. G.
    Adkison, K. K.
    Bonny, T.
    Millard, J.
    McCarty, D.
    HIV MEDICINE, 2009, 10 (02) : 116 - 124
  • [24] Neurocognitive Impairment among Treatment-Naive, HIV-Infected Individuals in Nigeria
    Royal, Walter, III
    Blattner, William
    Cherner, Mariana
    Abimiku, Alash'le
    Mamadu, Ibrahin
    Okwuasaba, Kanayo
    Agala, Ndidi
    Hendrix, Terence
    Alabi, Peter
    Alkali, Nura
    Gupta, Saurabh
    JOURNAL OF NEUROVIROLOGY, 2012, 18 : 94 - 95
  • [25] Pharmacokinetics of Sifuvirtide in Treatment-Naive and Treatment-Experienced HIV-Infected Patients
    Meng, Qingfang
    Dong, Tianhao
    Chen, Xin
    Tong, Baohui
    Qian, Xiaohong
    Che, Jinjing
    Cheng, Yuanguo
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (12) : 4038 - 4047
  • [26] Protecting the mucosal immune response in treatment-naive HIV-infected patients
    Tobin, Stacey C.
    AIDS, 2016, 30 (11) : N15 - N15
  • [27] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
    Lorenzen, Thore
    Stoehr, Albrecht
    Walther, Irene
    Plettenberg, Andreas
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
  • [28] Antiretroviral therapy adherence among treatment-naive HIV-infected patients
    Chakraborty, Apurba
    Qato, Dima M.
    Awadalla, Saria S.
    Hershow, Ronald C.
    Dworkin, Mark S.
    AIDS, 2020, 34 (01) : 127 - 137
  • [29] Neurocognitive Impairment among Treatment-Naive HIV-Infected Individuals in Nigeria
    Royal, W., III
    Cherner, M.
    Abimiku, A.
    Carr, J.
    Gartner, S.
    Adebamowo, C.
    Johnson, J.
    Alabi, P.
    Alkali, N.
    Mamadu, I.
    Okwuasaba, K.
    Agala, N.
    Gupta, S.
    Hendrix, T.
    Eyzaguirre, L. M.
    Aragbada, L.
    Ojo, B.
    Adebiyi, R. A.
    Blattner, W. A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 : 33 - 33
  • [30] CCR5 genotype and plasma β-chemokine concentration of Brazilian HIV-infected individuals
    Mikawa, AY
    Tagliavini, SA
    Costa, PI
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2002, 35 (11) : 1333 - 1337
12345